Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus | Zendy

Sonal Singh | Zendy; HsienYen Chang | Zendy; Thomas M. Richards | Zendy; Jonathan P. Weiner | Zendy; Jeanne M. Clark | Zendy; Jodi B Segal | Zendy

AI Assistant Blog Pricing

Open Access

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

Author(s) -

Sonal Singh,

HsienYen Chang,

Thomas M. Richards,

Jonathan P. Weiner,

Jeanne M. Clark,

Jodi B Segal

Publication year - 2013

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2013.2720

Subject(s) - medicine , sitagliptin , exenatide , acute pancreatitis , pancreatitis , diabetes mellitus , metformin , odds ratio , gastroenterology , type 2 diabetes , insulin , endocrinology

Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)-based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog